CEL-SCI Corporation (CVM) - 10-Q Summary
Business Context and Reporting Period
Company: CEL-SCI Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2019
Business Overview: CEL-SCI is a biopharmaceutical company focused on the development of Multikine (Leukocyte Interleukin, Injection) for the treatment of advanced primary head and neck cancer. The company is currently in the final stages of a multinational Phase 3 clinical trial. It also holds pre-clinical technology called LEAPS. The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2019 |
Six Months Ended Mar 31, 2018 |
Three Months Ended Mar 31, 2019 |
Three Months Ended Mar 31, 2018 |
|---|---|---|---|---|
| Grant Income | $277,183 | $210,586 | $150,769 | $114,271 |
| Total Operating Expenses | $9,618,245 | $9,363,034 | $4,457,369 | $4,337,707 |
| Operating Loss | $(9,341,062) | $(9,152,448) | $(4,306,600) | $(4,223,436) |
| Net Loss | $(5,201,779) | $(10,895,965) | $(6,447,681) | $(4,708,135) |
| Net Loss Per Share (Diluted) | $(0.19) | $(0.81) | $(0.22) | $(0.31) |
| Cash and Equivalents (Ending) | $5,514,013 | $3,062,189 | N/A (Balance Sheet Item) | |
| Total Assets | $24,755,207 | $29,586,422 | ||
| Total Liabilities | $23,799,685 | $29,585,506 | N/A (Balance Sheet Item) | |
| Stockholders' Equity | $955,522 | $916 |
Liquidity & Debt:
- Cash Flow: Net cash used in operating activities was $7.79 million for the six months ended March 31, 2019. This was partially offset by $3.3 million in proceeds from warrant exercises.
- Debt: The company has a significant lease liability of approximately $13.44 million related to its manufacturing facility (San Tomas lease), classified as a financing obligation.
- Derivative Liabilities: Total derivative liabilities (warrants) were $4.73 million as of March 31, 2019, down from $9.32 million at September 30, 2018.
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss for the six months ended March 31, 2019, decreased significantly to $5.2 million compared to $10.9 million in the prior year period. This improvement was primarily driven by a $4.6 million gain on derivative instruments (change in fair value of warrant liabilities) compared to a $0.2 million gain in the prior year.
- Quarterly Volatility: For the three months ended March 31, 2019, the company reported a net loss of $6.4 million, an increase from $4.7 million in the prior year quarter. This was due to a $0.97 million loss on derivative instruments in the current quarter versus a $1.15 million gain in the prior year quarter.
- Operating Expenses: Research and Development (R&D) expenses increased by $0.4 million year-over-year for the six-month period but decreased by $0.4 million for the three-month period. General and Administrative (G&A) expenses increased by $0.6 million in the most recent quarter, largely due to higher public relations costs and stock-based compensation.
- Cash Position: Cash and cash equivalents decreased by $4.8 million during the six-month period, reflecting the cash burn from operations despite financing inflows.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states there is "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and future liquidity needs. The financial statements do not include adjustments that might result from this uncertainty.
- Capital Needs: The company estimates it will incur an additional $6.3 million to complete the remainder of the Phase 3 clinical trial for Multikine. It plans to raise additional capital through corporate partnerships, debt issuances, and/or equity financings. There is no assurance that funding will be available on acceptable terms.
- Clinical Trial Status: The Phase 3 trial for Multikine in head and neck cancer is fully enrolled with 928 patients. The study endpoint is a 10% increase in overall survival, determined when 298 deaths occur in the comparator groups. As of March 31, 2019, $53.5 million has been spent on direct costs for this trial.
- Financing Arrangements: The company utilizes Securities Purchase Agreements (SPAs) with Ergomed (a CRO) to defer payments. Under these agreements, the company issues stock to Ergomed, which Ergomed may resell to pay down the debt. In the six months ended March 31, 2019, accounts payable were reduced by $1.7 million through this mechanism.
- Subsequent Events: Between April 1 and May 13, 2019, the company received approximately $7.6 million from the exercise of options and warrants.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to fund the estimated remaining $6.3 million for the Phase 3 trial given the current cash balance of $5.5 million and ongoing operating burn.
- Derivative Liability Volatility: Monitor the fair value of warrant liabilities, as fluctuations in the stock price significantly impact reported net income/loss (e.g., the $4.6M gain vs. $1.0M loss between periods).
- Phase 3 Trial Progress: Track the accumulation of deaths in the clinical trial to determine when the primary endpoint will be reached and if the 10% survival increase target is met.
- Capital Raising: Assess the success of recent and planned equity financings (including the $7.6M raised post-period) to ensure operations can continue without curtailment.
- Lease Obligations: Review the $13.4 million lease liability for the manufacturing facility and the terms of the 20-year lease, including the option to purchase the building.